pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
复制标题
DOI：
--
复制
发表时间：
1991-01
期刊：
影响因子：
11.2
通讯作者：
L. Schwartz;F. Koerner;S. Edgerton;J. Sawicka;M. Rio;J. Bellocq;P. Chambon;A. Thor
中科院分区：
文献类型：
--
作者：
L. Schwartz;F. Koerner;S. Edgerton;J. Sawicka;M. Rio;J. Bellocq;P. Chambon;A. Thor
72例晚期乳腺癌患者（42%骨，25%内脏，5.5%软组织，27.5%多部位转移）进行了评估，以确定肿瘤表达的雌激素调节蛋白pS2，雌激素受体（ER）或孕激素受体（PgR）的含量，和激素治疗的反应之间的关系。29%的肿瘤为pS2阳性，64%为ER阳性，29%为PgR阳性。在ER阳性患者（n = 43）中，15例（35%）浸润性癌中pS2免疫染色超过10%（这些被认为是pS2阳性）。24例ER阴性肿瘤中仅3例pS2阳性。观察到pS2表达与ER含量（P = 0.08）而非PgR含量之间存在弱相关性。在pS2阳性患者中，52%对激素治疗有部分或完全反应。在24%的pS2阳性患者中，疾病在治疗后稳定。相比之下，27%的pS2阴性患者获得部分或完全缓解。其中10%的患者病情稳定。未观察到治疗反应与ER或PgR之间的类似相关性。pS2阳性肿瘤对激素治疗有临床反应的几率大于ER或PgR阳性肿瘤。pS2表达可能定义了ER阳性肿瘤的一个子集，这些肿瘤更有可能对激素治疗产生反应。
Seventy-two patients with advanced breast carcinoma (42% bone, 25% visceral, 5.5% soft tissue, and 27.5% multiple site metastases) were evaluated to determine the relationship between tumor expression of the estrogen-regulated protein pS2, estrogen receptor (ER) or progesterone receptor (PgR) content, and response to hormonal therapy. Twenty-nine % of tumors were pS2 positive, 64% were ER positive, and 29% were PgR positive. Of the ER-positive patients (n = 43), 15 (35%) had greater than 10% of the invasive carcinoma which immunostained for pS2 (these were considered pS2 positive). Only 3 of 24 ER-negative tumors were pS2 positive. A weak association between pS2 expression and ER content (P = 0.08) but not PgR content was observed. Of pS2-positive patients, 52% had a partial or complete response to hormonal therapy. In 24% of pS2-positive patients the disease stabilized with treatment. In contrast, 27% of pS2-negative patients had a partial or complete response. In 10% of these patients the disease stabilized. Similar associations between therapeutic response and ER or PgR were not observed. The odds of having a clinical response to hormonal therapy was greater for pS2-positive than for ER- or PgR-positive tumors. pS2 expression may define a subset of ER-positive tumors that are more likely to respond to hormonal treatment.